Bovine somatotropin: review of an emerging animal technology

The Influence of Recombinant Bovine Somatotropin (rbST) on the Metabolic Profile and Milk Composition of Lactating Murrah Buffalo

The use of recombinant bovine somatotropin (rbST) leads to an increase in variable amounts of milk production in buffalo, but there is a lack of information on the influence of rbST on their metabolism. This study looked at the effects of a single 500 mg dose of rbST on the lipid profile, liver and kidney function, and physical, chemical, and cellular constitution of milk in 14 buffalo over 14 days, from the 100th day of lactation, compared with 14 animals in a control group. From the first day after rbST, there was a rise in beta-hydroxybutyrate (β-HBO), possibly due to higher dry matter intake or the biotransformation of NEFA into β-HBO. The treatment did not influence blood glucose, non-esterified fatty acids (NEFAs), triglycerides, cholesterol, total protein, albumin, AST, GGT, bilirubin, urea, or creatinine levels. In 71.3% of the buffalo, there was a gradual increase in milk production, with the maximal response occurring in the first week followed by a gradual decrease, whilst in 21.4%, the increase in production occurred between 7 and 10 days. Only 7.1% of the animals did not respond. On the 3rd, 5th, 7th, and 10th days after treatment, an increase was found in daily milk production between the two groups equal to 1.04, 1.52, 1.42, and 1.06 L, respectively. In relative terms, this means an increase in milk production, respectively, of 15.1%, 21.0%, 19.8%, and 15.1%. The constitution of the milk showed no difference in the amounts of fat, lactose, total solids, or somatic cell count; however, on the third day after rbST administration, there was a decrease in protein. Notably, from the fifth day, the protein values showed no statistical difference. It can be concluded that the use of rbST in buffalo from the 100th day of lactation is metabolically safe since the treatment neither caused imbalances in fat metabolism nor overloaded the liver or renal function, and the changes in milk composition were transient and limited to a decrease in milk protein.

Use of new recombinant proteins for ovarian stimulation in ruminants

Currently, gonadotropin products (follicle stimulating hormone, FSH, and luteinizing hormone, LH) used in animal reproduction are produced by extraction and purification from abattoir-derived pituitary glands. This method, relying on animal-derived materials, carries the potential risk of hormone contamination and pathogen transmission. Additionally, chorionic gonadotropins are extracted from the blood of pregnant mares (equine chorionic gonadotropin; eCG) or the urine of pregnant women (human chorionic gonadotropin; hCG). However, recent advancements have introduced recombinant gonadotropins for assisted animal reproduction therapies. The traditional use of FSH for superovulation has limitations, including labor requirements and variability in superovulation response, affecting the success of in vivo (SOV) and in vitro (OPU/IVEP) embryo production. FSH treatment for superstimulation before OPU can promote the growth of a homogenous follicular population and the recovery of competent oocytes suitable for IVEP procedures. At present, a single injection of a preparation of long-acting bovine recombinant FSH (rFSH) produced similar superovulation responses resulting in the production of good-quality in vivo and in vitro embryos. Furthermore, the treatment with eCG at FTAI protocol has demonstrated its efficacy in promoting follicular growth, ovulation, and P/AI, mainly in heifers and anestrous cows. Currently, treatment with recombinant glycoproteins with eCG-like activity (r-eCG) have shown promising results in increasing follicular growth, ovulation, and P/AI in cows submitted to P4/E2 -based protocols. Bovine somatotropin (bST) is a naturally occurring hormone found in cows. Recombinant bovine somatotropin (rbST), produced through genetic engineering techniques, has shown potential in enhancing reproductive outcomes in ruminants. Treatment with rbST has been found to improve P/IA, increase donor embryo production, and enhance P/ET in recipients. The use of recombinant hormones allows to produce non-animal-derived products, offering several advantages in assisted reproductive technologies for ruminants. This advancement opens up new possibilities for improving reproductive efficiency and success rates in the field of animal reproduction.

How to use recombinant bovine somatotropin in crossbred Holstein × Gyr (3/4 and 7/8) cows?

The aim of this study was to evaluate the effects of dose, start time, and application interval of recombinant bovine somatotropin (rbST) on performance, health, and reproduction parameters of crossbred Holstein × Gyr dairy cows (3/4 and 7/8). A 2 × 2 × 2 factorial study was designed to test the effects of application dose (250 mg rbST or 500 mg rbST), start of application (40 or 63 days in milk (DIM)), and application interval (12 or 14 days); 180 crossbred Holstein × Gyr cows were enrolled. Treatments with 500 mg rbST resulted in increased milk production, 3.5% fat-corrected milk (FCM), and energy-corrected milk (ECM). In the factorial design analysis, greater FCM, ECM, and milk solid production (kg/day) were observed when 500 mg rbST was started at 63 DIM, while 250 mg rbST resulted in greater milk production (kg/day), FCM, ECM, and milk solids (kg/day) when administered at 12-day intervals. Administration of 500 mg rbST resulted in an increase of days open and number of services per pregnancy (P = 0.01). Holstein × Gyr cows (3/4 and 7/8) presented a superior productive response to rbST when treated with 500 mg starting at 63 DIM and at 14-day intervals.

Effect of biostimulation on growth rate and reproductive development of Bos indicus dairy heifers

The present study aimed to compare the growth rate, feeding behavior, reproductive development, and concentrations of GH and leptin in Sahiwal heifers exposed to direct bull contact, bull contact through a fenceline, or isolated from bulls. Overall, 24 heifers were allotted to three treatment groups (n = eight/group) based on birth weight, body weight, and age. Heifers from the non-exposed group (NBE) remained isolated from bulls; heifers stimulated by fenceline bull contact (FBE) remained continuously exposed to bulls through a fenceline, and heifers with direct bull contact (DBE+FBE) had direct contact with a bull during 6 h/day plus continuous fenceline bull exposure for the entire 24 h period. It was considered that heifers attained puberty when progesterone concentration was >1 ng/mL. Biostimulated heifers achieved puberty at both a lower age and body weight (P < 0.05) than NBE heifers. Overall, average daily gain (g/day) was greater in DBE+FBE (516.3 ± 4.5) and FBE (501.6 ± 4.3) than in NBE (441.8 ± 2.9, respectively; P < 0.01). Leptin and growth hormone concentrations were significantly greater in FBE and DBE+FBE than NBE heifers. Both groups of biostimulated heifers devoted more time eating than NBE heifers, P < 0.05). In conclusion, biostimulation of Sahiwal heifers, either by exposing them to bulls through a fenceline or by both fenceline exposure and direct contact, reduced the age of puberty and increased growth performance. Overall, fenceline bull exposure can be recommended as an easy handling management to stimulate reproductive precocity and growth rate in heifers.

Agricultural methane emissions and the potential formitigation

Agriculture is the largest anthropogenic source of methane (CH₄), emitting 145 Tg CH₄y^-1 to the atmosphere in 2017. The main sources are enteric fermentation, manure management, rice cultivation and residue burning. There is significant potential to reduce CH₄ from these sources, with bottom-up mitigation potentials of approximately 10.6, 10, 2 and 1 Tg CH₄y^-1 from rice management, enteric fermentation, manure management and residue burning. Other system-wide studies have assumed even higher potentials of 4.8-47.2 Tg CH₄y^-1 from reduced enteric fermentation, and 4-36 Tg CH₄y^-1 from improved rice management. Biogas (a methane-rich gas mixture generated from the anaerobic decomposition of organic matter and used for energy) also has the potential to reduce unabated CH₄ emissions from animal manures and human waste. In addition to these supply side measures, interventions on the demand-side (shift to a plant-based diet and a reduction in total food loss and waste by 2050) would also significantly reduce methane emissions, perhaps in the order of greater than 50 Tg CH₄y^-1. While there is a pressing need to reduce emissions of long-lived greenhouse gases (CO₂ and N₂O) due to their persistence in the atmosphere, despite CH₄ being a short-lived greenhouse gas, the urgency of reducing warming means we must reduce any GHG emissions we can as soon as possible. Because of this, mitigation actions should focus on reducing emissions of all the three main anthropogenic greenhouse gases, including CH₄. This article is part of a discussion meeting issue 'Rising methane: is warming feeding warming? (part1)'.

Effects of bovine somatotropin on productive performance and Minas Padrão cheese

We aimed to evaluate the effects of two brands of bST (bovine somatoropin) on productive performance and on Minas Padrão cheese yield. Fifteen Girolando cows with more than 60 days of lactation were used. The animals were distributed in a randomized block design, according to days in milk, with three treatments (somatotropin A, somatotropin B, and control). The animals received a balanced diet with commercial concentrate and corn silage as roughage. It was measured milk yield and composition, dry matter intake, body condition score (BCS), and feeding behavior; it was compared by Tukey at 5.0% of significance level. Physical-chemical composition of Minas Padrão cheese was obtained from the different treatments, was also measured, being evaluated in a completely randomized design, and compared by Tukey at 1.0% of significance level. The dry matter intake per body weight lower in control treatment (p < 0.05) was equal to 2.85, somatotropin A was equal to 3.17, and somatotropin B was equal to 3.17. Animals that received bST showed higher milk production (p < 0.05), with control being 17.56 kg/day, somatotropin A 21.12 kg/day, and somatotropin B 20.69 kg/day. The physical-chemical composition of milk showed significant differences (p < 0.05) for the fat, protein, and dry extract contents. The somatotropin applications also influenced the BCS (p < 0.05) and the feeding behavior in time for total intake, time spent with rumination, and idleness. The application of bST increased milk yield and technical and economic yields of Minas Padrão cheese did not show significant differences between treatments.

Bovine Somatotropin Alters Myosin Heavy Chains and Beta Receptors in Skeletal Muscle of Feedlot Heifers with Little Impact on Live or Carcass Performance

The objective was to determine whether recombinant bovine somatotropin (rbST) enhanced live performance,skeletal muscle biological activity, and beta-adrenergic receptor expression of feedlot heifers during the finishing phase. Heifers (n = 16; initial body weight = 457 ± 3 kg) were randomly assigned to pens (4 pens/treatment; 2 heads/pen) and treatment: (1) no rbST (Control); (2) 500 mg/hd of sometribove zinc at day 0 and 14 (rbST; Posilac®; Elanco AnimalHealth, Greenfield, IN). Longissimus muscle biopsies for muscle chemistry were collected on day 0, 14, 28, 42, and 56. The rbST heifers had increased expression of AMP-activated protein kinase alpha and beta 3 adrenergic receptor (P &lt; 0.05). Day of the study affected the expression of myosin heavy chain-IIA (MHC-IIA), MHC-IIX, beta 2 adrenergic receptor, peroxisome proliferator-activated receptor gamma, and stearoyl-CoA desaturase (P &lt; 0.05). Day had a significant effect on muscle fiber cross-sectional area and proportion (P &lt; 0.05). As days on feed increased, the area of MHC-I fibers decreased whereas MHC-IIA and IIX area increased (P &lt; 0.05). The rbST heifers had decreased proportions of MHC-I fibers and increased proportions of MHC-IIX fibers (P &lt; 0.05). The greatest density of Paired Box 7-positive cells was on day 0, 28, and 42 (P &lt; 0.05), and the greatest density of Myogenic factor 5-positive cells was on day 42 and 56 (P &lt; 0.05). Also, the greatest density of cells positive for Paired Box 7:Myogenic factor 5 was measured on day 28 (P &lt; 0.05). These data indicate that, as days on feed increase, the effects of skeletal muscle biological activity are not dependent on rbST administration but may be more due to physiological changes occurring as the animal reaches physio-logical maturity.

Recombinant Technologies to Improve Ruminant Production Systems: The Past, Present and Future

The use of recombinant technologies has been proposed as an alternative to improve livestock production systems for more than 25 years. However, its effects on animal health and performance have not been described. Thus, understanding the use of recombinant technology could help to improve public acceptance. The objective of this review is to describe the effects of recombinant technologies and proteins on the performance, health status, and rumen fermentation of meat and milk ruminants. The heterologous expression and purification of proteins mainly include eukaryotic and prokaryotic systems like Escherichia coli and Pichia pastoris. Recombinant hormones have been commercially available since 1992, their effects remarkably improving both the reproductive and productive performance of animals. More recently the use of recombinant antigens and immune cells have proven to be effective in increasing meat and milk production in ruminant production systems. Likewise, the use of recombinant vaccines could help to reduce drug resistance developed by parasites and improve animal health. Recombinant enzymes and probiotics could help to enhance rumen fermentation and animal efficiency. Likewise, the use of recombinant technologies has been extended to the food industry as a strategy to enhance the organoleptic properties of animal-food sources, reduce food waste and mitigate the environmental impact. Despite these promising results, many of these recombinant technologies are still highly experimental. Thus, the feasibility of these technologies should be carefully addressed before implementation. Alternatively, the use of transgenic animals and the development of genome editing technology has expanded the frontiers in science and research. However, their use and implementation depend on complex policies and regulations that are still under development.

Effect of recombinant bovine somatotropin (rbST) treatment on follicular population and development in non-lactating dairy cows

The aim of this study was to evaluate the long-term effects of recombinant bovine somatotropin (rbST) on follicle population and ovulatory follicle development in non-lactating dairy cows. Twenty-one Jersey cows were allocated in rbST (n=11) or control (n=10) groups. On day -60, cows in rbST group received 500 mg of somatotropin (s.c. Lactotropin®, Elanco). On day 0, control and rbST cows received an intravaginal progesterone-releasing device (1.9 g, CIDR^®, Zoetis) and GnRH (100 mg, IM, Factrel^®, Zoetis). On day 8, cows received PGF2α (25 mg, IM, Lutalyse®, Zoetis) and the CIDR^® was removed. Twelve hours after device removal (D8), serum, follicular fluid and granulosa cells samples were collected. Serum and follicular concentration of estradiol (E2) and progesterone (P4) were analyzed. Total RNA was extracted from granulosa cells to measure gene expression of LHCGR, STAR, HSD-3B1, CYP11A1, CYP19A1, CYP17A1, IGFR and PAPPA by real-time PCR. Ultrasonography was performed on days -60, -53, -46, -14, -7, 0 and 8 for antral follicle count. Results were analyzed by repeated measures ANOVA and t-test. There was no effect of rbST treatment on the number of follicles during the 60 days period, as well as no effect on serum and follicular fluid E2 and follicular fluid P4 at the moment of follicle aspiration. There was a reduction in PAPPA (P = 0.006), CYP11A1 (P = 0.04) and CYP19A1 (P = 0.002) mRNA levels in granulosa cells of the pre-ovulatory follicle of rbST treated cows. In conclusion, a single dose of rbST did not have long-term effects on antral follicle population, serum and follicular E2/P4 concentrations in non-lactating dairy cows. Despite that, rbST injection decreased granulosa cell expression of genes related to steroidogenesis in the pre-ovulatory follicle.

Uso da somatotropina recombinante bovina em búfalas leiteiras II: metabolismos energético e mineral

RESUMO Avaliou-se a influência da somatotropina recombinante bovina (rbST) sobre os metabolismos energético e mineral de búfalas entre 63e 154 dias em lactação. Foram utilizadas 22 búfalas, distribuídas em dois grupos experimentais: grupo rbST - aplicação de 500mg de rbST a cada 14 dias; grupo Controle - sem aplicação de rbST. A cada sete dias, foram coletadas amostras de sangue para a determinação do perfil bioquímico e mensuraram-se a produção de leite e o escore de condição corporal dos animais. As médias dos parâmetros estudados para os grupos rbST e Controle foram, respectivamente: produção de leite (PL): 6,44kg vs. 6,68kg; escore de condição corporal-ECC (1-5): 3,51 vs. 3,57; glicose: 70,58 vs. 64,81mg/dL (P = 0,0003); colesterol: 132,38 vs. 133,40mg/dL; triglicérides: 29,18 vs. 28,32mg/dL; proteína total: 8,57 vs. 8,75g/dL; albumina: 3,47 vs. 3,60g/dL; ureia: 32,46 vs. 33,86mg/dL; creatinina: 1,27 vs. 1,39mg/dL; cálcio:10,25 vs. 10,73mg/dL; fósforo:5,76 vs. 5,62mg/dL; e magnésio:3,70 vs. 3,70mg/dL. O uso de 500mg de rbSTinfluenciou o metabolismo da glicose, porém não modificou a PL, o ECC e os níveis dos demais parâmetros metabólicos estudados.

A 100-Year Review: Practical female reproductive management

Basic knowledge of mechanisms controlling reproductive processes in mammals was limited in the early 20th century. Discoveries of physiologic processes and mechanisms made early in the last century laid the foundation to develop technologies and programs used today to manage and control reproduction in dairy cattle. Beyond advances made in understanding of gonadotropic support and control of ovarian and uterine functions in basic reproductive biology, advancements made in artificial insemination (AI) and genetics facilitated rapid genetic progress of economically important traits in dairy cattle. Technologies associated with management have each contributed to the evolution of reproductive management, including (1) hormones to induce estrus and ovulation to facilitate AI programs; (2) pregnancy diagnosis via ultrasonography or by measuring conceptus-derived pregnancy-associated glycoproteins; (3) estrus-detection aids first devised for monitoring only physical activity but that now also quantitate feeding, resting, and rumination times, and ear temperature; (4) sex-sorted semen; (5) computers and computerized record software packages; (6) handheld devices for tracking cow location and retrieving cow records; and (7) genomics for increasing genetic progress of reproductive and other economically important traits. Because of genetic progress in milk yield and component traits, the dairy population in the United States has been stable since the mid 1990s, with approximately 9 to 9.5 million cows. Therefore, many of these technologies and changes in management have been developed in the face of increasing herd size (4-fold since 1990), and changes from pastoral or dry-lot dairies to increased housing of cows in confinement buildings with freestalls and feed-line lockups. Management of groups of "like" cows has become equally important as management of the one. Management teams, including owner-managers, herdsmen, AI representatives, milkers, and numerous consultants dealing with health, feeding, and facilities, became essential to develop working protocols, monitor training and day-to-day chores, and evaluate current trends and revenues. Good management teams inspect and follow through with what is routinely expected of workers. As herd size will undoubtedly increase in the future, practical reproductive management must evolve to adapt to the new technologies that may find more herds being milked robotically and applying technologies not yet conceived or introduced.

Uso da somatotropina recombinante bovina em búfalas leiteiras I: produção e composição físico-química do leite

RESUMO Objetivou-se avaliar a influência da somatotropina recombinante bovina (rbST) sobre a produção e os constituintes do leite de búfalas entre 63 e 154 dias em lactação. Foram utilizadas 22 búfalas, distribuídas em dois grupos experimentais: grupo rbST - aplicação de 500 mg de rbST a cada 14 dias; grupo controle - sem aplicação de rbST. A cada sete dias, foi aferida a produção de leite de todas as búfalas e coletada uma amostra para análise físico-química. As variáveis produtivas e as oriundas de análises laboratoriais foram avaliadas como medidas repetidas no tempo, utilizando-se o comando Repeated gerado pelo procedimento GLM do SAS. A média dos parâmetros estudados para os grupos rbST e controle foram, respectivamente: produção de leite - 6,54 vs. 6,68 kg; gordura - 6,31 vs. 6,34%; proteína 3,86 vs. 3,81%; lactose - 4,96 vs. 5,02%; sólidos totais - 16,05 vs. 16,03%; extrato seco desengordurado - 9,75 vs. 9,74%; contagem de células somáticas - 329,90 vs. 171,68 (x 1000/mL); e elecondutividade - 2,87 vs. 2,81mS/cm. A utilização de 500mg de rbST administrados quinzenalmente, entre 63 e 154 dias em lactação não alterou a produção de leite, a proporção dos constituintes e a CCS do leite de búfalas leiteiras.

The Fate of Synthetic and Endogenous Hormones Used in the US Beef and Dairy Industries and the Potential for Human Exposure

PURPOSE OF REVIEW

Growth-enhancing chemicals used by the beef and dairy industries may be bioavailable to humans via milk, meat, and other environmental matrices. This review evaluates the potential for environmental transport and bioavailability of the active chemical to humans.

RECENT FINDINGS

Bovine somatostatin is detectable in milk; however, there is no evidence that the protein persists in the environment nor that it is active in humans. In contrast, steroids are transported through milk and meat to humans where they may exert biological activity. Furthermore, environmental matrices such as raw water and dust may also allow for the environmental transport and bioavailability of steroids to humans. Endogenous and exogenous steroids can be found in the meat, milk, and waste materials produced by cattle. While the concentrations may be low, exposure to these matrices, most notably dairy products made with whole milk, can be a source of exogenous steroids to humans.

Udder characteristics and relationship to efficiency of milk production

Milk yield is ultimately constrained by the number of mammary secretory cells and the amount produced by each cell; increasing yield during early lactation is associated with increased output per cell, whilst decreasing yield during declining lactation correlates with reduced number of cells. Overall, yield is highly correlated with mass of secretory tissue but strategic control of lactation involves a galactopoietic complex of hormones including GH, prolactin and oxytocin acting to ensure efficient milk ejection and maintenance of secretion. Fine control, on the other hand, is achieved locally within the mammary gland by an autocrine mechanism which matches supply of milk to demand. The feedback inhibitor of lactation (FIL) is a milk protein which is inhibitory to secretion, so as milk accumulates between milkings, secretion rate gradually falls. The more frequently FIL is removed by milking, the greater the overall secretion rate. Storage of milk occurs within secretory tissue (alveolar milk) but also in the cistern (cisternal milk); FIL is effective in alveolar milk but not in cisternal milk, because it is then remote from its site of action. Therefore predictions would be that for a given mass of secretory tissue, large-cisterned cows should produce more milk, be more tolerant of infrequent milking but be less responsive to frequent milking. Methods developed by us for determining cisternal and alveolar milk storage spaces have obtained statistically proven support for the latter two predictions in dairy cows; the first prediction has been proven in goats. It has been shown that cisternal milk fraction increases during the course of lactation and with increasing parity. It is now intended to investigate the feasibility of incorporating storage characteristics into future selection strategies.

Recombinant bovine somatotropin on heifer’s biometric measures, bodyweight, blood metabolites, and dry matter intake predictions

This study aimed to determine the influence of sustained-release recombinant bovine somatotropin (rbST) injections on biometrics measures, bodyweight (BW), average BW gain, observed and predicted DM intake, accuracy of recent methods to estimate DM intake, blood metabolites, haematological profile and rectal temperature in dairy heifers. Thirty Holstein heifers (132 ± 27 kg BW and 6.2 ± 0.35 months of age) were used in a complete randomised design experiment. Heifers were assigned to treatments: (1) Control (CON), 250 mL of saline solution, or (2) rbST, 250 mg of sustained-release rbST every 15 days. Treatments were injected in the subcutaneous of ischiorectal fossa or subscapular region in a regular alternating manner (right and left side) every 15 days throughout a period of 90 days. Prediction of DM intake was calculated using either non-linear or linear models for heifers in tropical conditions. rbST injections increased the average values of thoracic perimeter, length, and rump width in heifers. rbST-treated heifers had higher average BW and BW gain than CON. Regardless of the model applied, both observed and predicted DM intake were higher for heifers rbST-treated in relation to CON. Non-linear model was accurate without significant bias. rbST injections elevated blood glucose and high-density lipoprotein cholesterol concentration in heifers. No differences were detected on haematological profile and rectal temperature of heifers. rbST injections every 15 days to growing heifers promoted animal performance by increasing biometrics measures and BW gain. In addition, non-linear model was accurate to predict DM intake of heifers.

TRIENNIAL LACTATION SYMPOSIUM/BOLFA:Historical perspectives of lactation biology in the late 20th and early 21st centuries

The latter half of the 20th century and the early portion of the 21st century will be recognized as the "Golden Age" of lactation biology. This period corresponded with the rise of systemic, metabolomic, molecular, and genomic biology. It includes the discovery of the structure of DNA and ends with the sequencing of the complete genomes of humans and all major domestic animal species including the dairy cow. This included the ability to identify polymorphisms in the nucleic acid sequence, which can be tied to specific differences in cellular, tissue, and animal performance. Before this period, classical work using endocrine ablation and replacement studies identified the mammary gland as an endocrine-dependent organ. In the early 1960s, the development of RIA and radioreceptor assays permitted the study of the relationship between endocrine patterns and mammary function. The ability to measure nucleic acid content of tissues opened the door to study of the factors regulating mammary growth. The development of high-speed centrifugation in the 1960s allowed separation of specific cell organelles and their membranes. The development of transmission and scanning electron microscopy permitted the study of the relationship between structure and function in the mammary secretory cell. The availability of radiolabeled metabolites provided the opportunity to investigate the metabolic pathways and their regulation. The development of concepts regarding the coordination of metabolism to support lactation integrated our understanding of nutrient partitioning and homeostasis. The ability to produce recombinant molecules and organisms permitted enhancement of lactation in farm animal species and the production of milk containing proteins of value to human medicine. These discoveries and others contributed to vastly increased dairy farm productivity in the United States and worldwide. This review will include the discussion of the centers of excellence and scientists who labored in these fields to produce the harvest of knowledge we enjoy today.

Changing innovation into a registered product: From concept to regulatory approval

Innovation in animal health pharmaceuticals is important to address unmet and underserved medical needs, and often comes from products initially developed for human medicine. The purpose of the review is to help readers understand how breakthroughs from human biotechnology may be developed for use in veterinary medicine, while understanding the key drivers to success, the difficulties of regulatory approval, and the realistic risks and rewards of developing applications for animals. The types of human drugs which may be useful for veterinary applications are reviewed, including examples. The regulatory path is discussed, with a review of the various oversight agencies, and the categories of data required to be submitted, including safety, efficacy, manufacturing, environmental impact and human food safety. In conclusion, the cost, development time, and barriers to innovation in veterinary medical pharmaceuticals are discussed.

Imagining the ideal dairy farm

Practices in agriculture can have negative effects on the environment, rural communities, food safety, and animal welfare. Although disagreements are possible about specific issues and potential solutions, it is widely recognized that public input is needed in the development of socially sustainable agriculture systems. The aim of this study was to assess the views of people not affiliated with the dairy industry on what they perceived to be the ideal dairy farm and their associated reasons. Through an online survey, participants were invited to respond to the following open-ended question: "What do you consider to be an ideal dairy farm and why are these characteristics important to you?" Although participants referenced social, economic, and ecological aspects of dairy farming, animal welfare was the primary issue raised. Concern was expressed directly about the quality of life for the animals, and the indirect effect of animal welfare on milk quality. Thus participants appeared to hold an ethic for dairy farming that included concern for the animal, as well as economic, social, and environmental aspects of the dairy system.

Effect of administration of recombinant bovine somatotropin on health and performance of lactating dairy cows diagnosed with hyperketonemia

The effect of administering recombinant bovine somatotropin (rbST) to cows with hyperketonemia during the early postpartum period on health, metabolic parameters, milk production, and early reproductive performance was evaluated in a double-blinded clinical trial. Cows from 8 dairy herds in New York State were tested weekly between 3 and 16d in milk for elevated serum β-hydroxybutyrate. Cows were enrolled in the study when blood β-hydroxybutyrate was ≥1.3mmol/L for the first time. Enrolled cows were randomly assigned to a treatment (n=273) or placebo control (n=270) group. Treated cows were given 325mg of rbST subcutaneously on the day of enrollment and again 14d later. Control cows received the same regimen except the syringe contained only the carrier without somatotropin. After enrollment, blood samples were collected weekly for 4wk and submitted to the laboratory to be analyzed for selected metabolites. Risk ratios for clinical diseases subsequent to treatment were calculated using Poisson regression. Continuous data were analyzed using linear mixed models. Time to first insemination was assessed with survival analysis. In the 42d following the first administration of rbST, incidence risks of displaced abomasum, clinical ketosis, metritis, clinical mastitis, and lameness were not different between treatment groups. Cows treated with rbST had a slightly lower body condition score 28d after enrollment compared with control cows. In the 4wk following enrollment, serum nonesterified fatty acids and aspartate amino-transferase were slightly higher for treated than control cows, respectively. Serum glucose, calcium, haptoglobin, and β-hydroxybutyrate were similar between groups. Treatment had no effect on resolution of hyperketonemia in any of the 4wk after enrollment. Milk production in either of the 2-wk periods after each treatment was not different between treated and control cows. Furthermore, milk production was not different between groups from enrollment to 98d in milk (42.6±0.6 and 42.1±0.7kg/d for treatment and control groups, respectively). Treatment had no effect on time to first insemination (83 and 74d in milk for treatment and control groups, respectively; hazard ratio=0.72) or first insemination pregnancy risk (27 and 29% for treatment and control groups, respectively; risk ratio=0.92). Based on the current results, it is not recommended to use a low dose of rbST as therapy for cows with hyperketonemia.

Effects of recombinant bovine somatotropin during the periparturient period on innate and adaptive immune responses, systemic inflammation, and metabolism of dairy cows

The aim of this experiment was to determine effects of treating peripartum dairy cows with body condition score ≥3.75 with recombinant bovine somatotropin (rbST) on immune, inflammatory, and metabolic responses. Holstein cows (253±1d of gestation) were assigned randomly to 1 of 3 treatments: untreated control (n=53), rbST87.5 (n=56; 87.5mg of rbST), and rbST125 (n=57; 125mg of rbST). Cows in the rbST87.5 and rbST125 treatments received rbST weekly from -21 to 28d relative to calving. Growth hormone, insulin-like growth factor 1, haptoglobin, tumor necrosis factor α, nonesterified fatty acids, β-hydroxybutyrate, glucose, and cortisol concentrations were determined weekly from -21 to 21d relative to calving. Blood sampled weekly from -14 to 21d relative to calving was used for hemogram and polymorphonuclear leukocyte (PMNL) expression of adhesion molecules, phagocytosis, and oxidative burst. Cows were vaccinated with ovalbumin at -21, -7, and 7d relative to calving, and blood was collected weekly from -21 to 21d relative to calving to determine IgG anti-ovalbumin concentrations. A subsample of cows had liver biopsied -21, -7, and 7d relative to calving to determine total lipids, triglycerides, and glycogen content. Growth hormone concentrations prepartum (control=11.0±1.2, rbST87.5=14.1±1.2, rbST125=15.1±1.3ng/mL) and postpartum (control=14.4±1.1, rbST87.5=17.8±1.2, rbST125=21.8±1.1ng/mL) were highest for rbST125 cows. Cows treated with rbST had higher insulin-like growth factor 1 concentrations than control cows (control=110.5±4.5, rbST87.5=126.2±4.5, rbST125=127.2±4.5ng/mL) only prepartum. Intensity of L-selectin expression was higher for rbST125 than for control and rbST87.5 cows [control=3,590±270, rbST87.5=3,279±271, rbST125=4,371±279 geometric mean fluorescence intensity (GMFI)] in the prepartum period. The PMNL intensities of phagocytosis (control=3,131±130, rbST87.5=3,391±133, rbST125=3,673±137 GMFI) and oxidative burst (control=9,588±746, rbST87.5=11,238±761, rbST125=12,724±781 GMFI) were higher for rbST125 cows than for control cows during the prepartum period. Concentrations of serum IgG anti-ovalbumin tended to be higher for rbST125 cows than for control cows (control=0.75±0.11, rbST87.5=0.94±0.10, rbST125=1.11±0.11 optical density) in the prepartum period. Haptoglobin concentration was significantly reduced 7d postpartum for rbST125 treatment compared with control and rbST87.5 treatments (control=2.74±0.28, rbST87.5=2.81±0.28, rbST125=1.87±0.28 optical density). Although treatment tended to affect postpartum β-hydroxybutyrate (control=747.5±40.2, rbST87.5=753.2±40.1, rbST125=648.8±39.7 µmol/L), it did not affect liver contents of total lipids, triglycerides, or glycogen. Incidence of metritis among rbST125 cows was reduced compared with that in control cows (control=23.1, rbST87.5=18.0, rbST125=7.8%). Treatment of dairy cows with 125mg of rbST improved innate immune responses and IgG concentration, with limited effects on metabolism.

Meta-analysis of the effects of sometribove zinc suspension on the production and health of lactating dairy cows

OBJECTIVE

To provide an updated evaluation of the efficacy and safety of sometribove zinc suspension (rbST-Zn), a form of recombinant bovine somatotropin, in lactating dairy cows.

DESIGN

Meta-analysis.

SAMPLE

26 studies published in peer-reviewed journals or reviewed by a regulatory agency.

PROCEDURES

To be included, a study had to involve the use of the rbST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days postpartum), dose (500 mg, q 14 d), and route (SC).

RESULTS

For cows treated with rbST-Zn, mean milk, 3.5% fat-corrected milk, fat, and protein yields were increased by 4.00, 4.04, 0.144, and 0.137 kg/d (8.8, 8.89, 0.32, and 0.30 lb/d), respectively; however, the concentration of milk components did not change. Pregnancy proportion for the first 2 breeding cycles was increased by 5.4%, and pregnancy proportion for the duration of the trial was reduced by 5.5% for rbST-Zn-treated cows, compared with proportions for untreated cows. Mean body condition score (1 to 5 scale) was reduced by 0.06 points during the period of rbST-Zn use for treated cows. Administration of rbST-Zn had no effect on milk somatic cell count, the number of days to pregnancy, or inseminations per pregnancy; rates of fetal loss, twins, cystic ovaries, clinical lameness, lameness lesions, or traumatic lesions of the integumentary system; and odds of clinical mastitis or culling.

CONCLUSIONS AND CLINICAL RELEVANCE

Results indicated that rbST-Zn administration to dairy cows effectively increases milk production with no adverse effects on cow health and well-being.

Invited review: Enteric methane in dairy cattle production: quantifying the opportunities and impact of reducing emissions

Many opportunities exist to reduce enteric methane (CH4) and other greenhouse gas (GHG) emissions per unit of product from ruminant livestock. Research over the past century in genetics, animal health, microbiology, nutrition, and physiology has led to improvements in dairy production where intensively managed farms have GHG emissions as low as 1 kg of CO2 equivalents (CO2e)/kg of energy-corrected milk (ECM), compared with >7 kg of CO2 e/kg of ECM in extensive systems. The objectives of this review are to evaluate options that have been demonstrated to mitigate enteric CH4 emissions per unit of ECM (CH4/ECM) from dairy cattle on a quantitative basis and in a sustained manner and to integrate approaches in genetics, feeding and nutrition, physiology, and health to emphasize why herd productivity, not individual animal productivity, is important to environmental sustainability. A nutrition model based on carbohydrate digestion was used to evaluate the effect of feeding and nutrition strategies on CH4/ECM, and a meta-analysis was conducted to quantify the effects of lipid supplementation on CH4/ECM. A second model combining herd structure dynamics and production level was used to estimate the effect of genetic and management strategies that increase milk yield and reduce culling on CH4/ECM. Some of these approaches discussed require further research, but many could be implemented now. Past efforts in CH4 mitigation have largely focused on identifying and evaluating CH4 mitigation approaches based on nutrition, feeding, and modifications of rumen function. Nutrition and feeding approaches may be able to reduce CH4/ECM by 2.5 to 15%, whereas rumen modifiers have had very little success in terms of sustained CH4 reductions without compromising milk production. More significant reductions of 15 to 30% CH4/ECM can be achieved by combinations of genetic and management approaches, including improvements in heat abatement, disease and fertility management, performance-enhancing technologies, and facility design to increase feed efficiency and life-time productivity of individual animals and herds. Many of the approaches discussed are only partially additive, and all approaches to reducing enteric CH4 emissions should consider the economic impacts on farm profitability and the relationships between enteric CH4 and other GHG.

The role of productivity in improving the environmental sustainability of ruminant production systems

The global livestock industry is charged with providing sufficient animal source foods to supply the global population while improving the environmental sustainability of animal production. Improved productivity within dairy and beef systems has demonstrably reduced resource use and greenhouse gas emissions per unit of food over the past century through the dilution of maintenance effect. Further environmental mitigation effects have been gained through the current use of technologies and practices that enhance milk yield or growth in ruminants; however, the social acceptability of continued intensification and use of productivity-enhancing technologies is subject to debate. As the environmental impact of food production continues to be a significant issue for all stakeholders within the field, further research is needed to ensure that comparisons among foods are made based on both environmental impact and nutritive value to truly assess the sustainability of ruminant products.

Somatotropic gene response to recombinant growth hormone treatment in buffalo leucocytes

The use of recombinant bovine growth hormone (rbGH) to increase milk yield in cows is banned in some countries. In others, where it is authorised, it has triggered harsh debates on labelling of dairy products. If many studies have been performed on bovines, there is a lack of information on buffaloes, which are sometimes treated with rbGH and re-present an important economical resource for dairy products in some countries. Analytical methods with legal value for surveillance of rbGH treatments do not yet exist. Research on gene expression biomarkers is one of the most promising approaches to this purpose. For this reason, we treated five buffaloes for 10 weeks with a sustained-release formulation of rbGH and analysed the response of 20 somatotropic axis genes in leucocytes by real-time polymerase chain reaction. Overall changes in gene expression levels were of low magnitude and sometimes affected by the 'time' factor. Only the IGFBP-1 gene showed a significant under-expression (about two-fold; p <0.001) in treated animals. Taken together, these results give evidence that expression analysis of the somatotropic axis genes in leucocytes is little helpful for discrimination of rbGH-treated buffaloes, but do not exclude that another array of genes could provide useful patterns of variation.

Somatotropic gene response to recombinant growth hormone treatment in buffalo leucocytes

The use of recombinant bovine growth hormone (rbGH) to increase milk yield in cows is banned in some countries. In others, where it is authorised, it has triggered harsh debates on labelling of dairy products. If many studies have been performed on bovines, there is a lack of information on buffaloes, which are sometimes treated with rbGH and re-present an important economical resource for dairy products in some countries. Analytical methods with legal value for surveillance of rbGH treatments do not yet exist. Research on gene expression biomarkers is one of the most promising approaches to this purpose. For this reason, we treated five buffaloes for 10 weeks with a sustained-release formulation of rbGH and analysed the response of 20 somatotropic axis genes in leucocytes by real-time polymerase chain reaction. Overall changes in gene expression levels were of low magnitude and sometimes affected by the 'time' factor. Only the IGFBP-1 gene showed a significant under-expression (about two-fold; p <0.001) in treated animals. Taken together, these results give evidence that expression analysis of the somatotropic axis genes in leucocytes is little helpful for discrimination of rbGH-treated buffaloes, but do not exclude that another array of genes could provide useful patterns of variation.

Hormone variations in serum and milk of buffaloes (Bubalus bubalis) as potential indicators of treatment with recombinant bovine somatotropin

Recombinant bovine somatotropin (rbST) is used to increase milk yield in cows, but it has been forbidden in some countries and in the EU. However, rbST misuse represents a concern in both bovine and buffalo dairy production. A number of studies on rbST treatment have been performed on bovines, but there are few data on buffaloes. In this study, we treated eight lactating buffaloes with biweekly injections of a slow-release formulation of rbST, for five cycles of administration, and analysed total ST and insulin-like growth factor 1 (IGF-1) variations in serum and IGF-1 in milk. The aim was to assess their power as potential indicators of rbST-treatment. Blood was collected on days 2, 5, 9 and 14 of each cycle, and milk on days 2, 9 and 14 of cycles 2 and 5. Results showed an extraordinary increase in ST levels on day 2 in treated animals, followed by a rapid decrease over the following days, while a significant increase in IGF-1 was observed both in serum and in milk throughout most of each cycle. These results suggest that serum ST levels are a good indicator of treatment. However, the rapid decrease after the peak limits the useful period of sample collection.

Viabilidade financeira da utilização de quatro ordenhas nos primeiros 21 dias da lactação em vacas mestiças F1 Holandês/Zebu

Avaliou-se financeiramente o efeito de quatro ordenhas diárias nos primeiros 21 dias da lactação, seguidas de duas ordenhas diárias, com ou sem a sucção de leite pelo bezerro em um dos tetos durante a ordenha. Foram utilizadas 53 vacas F1 Holandês/Zebu multíparas. A produção e a composição do leite foram mensuradas a cada quatro dias até o 33° dia da lactação e, posteriormente, a cada 15 dias. Como indicador do desempenho financeiro dos diferentes grupos, foi utilizada a margem bruta. O experimento foi desenvolvido em delineamento inteiramente ao acaso, em arranjo fatorial 2x2. As produções médias de leite foram 16,7, 17,2, 19,0 e 18,9kg/d (PÂ0,01) para vacas ordenhadas duas e quatro vezes por dia, com ou sem a sucção do leite pelo bezerro durante a ordenha, respectivamente. O aumento da frequência de ordenhas nos primeiros 21 dias da lactação proporcionou incremento na produção de dois litros/dia e 17,3% na margem bruta estimada com a venda de leite.

Associations between novel single nucleotide polymorphisms in the Bos taurus growth hormone gene and performance traits in Holstein-Friesian dairy cattle

Growth hormone, produced in the anterior pituitary gland, stimulates the release of insulin-like growth factor-I from the liver and is of critical importance in the control of nutrient utilization and partitioning for lactogenesis, fertility, growth, and development in cattle. The aim of this study was to discover novel polymorphisms in the bovine growth hormone gene (GH1) and to quantify their association with performance using estimates of genetic merit on 848 Holstein-Friesian AI (artificial insemination) dairy sires. Associations with previously reported polymorphisms in the bovine GH1 gene were also undertaken. A total of 38 novel single nucleotide polymorphisms (SNP) were identified across a panel of 22 beef and dairy cattle by sequence analysis of the 5' promoter, intronic, exonic, and 3' regulatory regions, encompassing approximately 7 kb of the GH1 gene. Following multiple regression analysis on all SNP, associations were identified between 11 SNP (2 novel and 9 previously identified) and milk fat and protein yield, milk composition, somatic cell score, survival, body condition score, and body size. The G allele of a previously identified SNP in exon 5 at position 2141 of the GH1 sequence, resulting in a nonsynonymous substitution, was associated with decreased milk protein yield. The C allele of a novel SNP, GH32, was associated with inferior carcass conformation. In addition, the T allele of a previously characterized SNP, GH35, was associated with decreased survival. Both GH24 (novel) and GH35 were independently associated with somatic cell count, and 3 SNP, GH21, 2291, and GH35, were independently associated with body depth. Furthermore, 2 SNP, GH24 and GH63, were independently associated with carcass fat. Results of this study further demonstrate the multifaceted influences of GH1 on milk production, fertility, and growth-related traits in cattle.

Mitigation of greenhouse gas emissions in the production of fluid milk

Global climate change, driven by the buildup of greenhouse gas (GHG) emissions in the atmosphere, is challenging the dairy industries in the United States and throughout the world to develop sustainable initiatives to reduce their environmental impact. The U.S. dairy industry has committed to lowering the GHG emissions, primarily CH(4), N(2)O, and CO(2), in each sector of the fluid milk supply chain which extends from the farm, to the processing plant, and to distribution of the packaged product, where it is refrigerated by the retailer and then the consumer. This chapter provides an overview of the life cycle analysis (LCA) technique and its use in identifying the GHG emissions in each sector of the fluid milk supply chain, from cradle to grave, and the best practices and research that is currently being conducted to reduce or mitigate GHG emissions in each sector. We also discuss the use of on-farm and off-farm process simulation as tools for evaluating on-farm mitigation techniques, off-farm alternative processing scenarios, and use of alternative energy management practices.

Factors affecting methane production and mitigation in ruminants

Methane (CH(4)) is the second most important greenhouse gas (GHG) and that emitted from enteric fermentation in livestock is the single largest source of emissions in Japan. Many factors influence ruminant CH(4) production, including level of intake, type and quality of feeds and environmental temperature. The objectives of this review are to identify the factors affecting CH(4) production in ruminants, to examine technologies for the mitigation of CH(4) emissions from ruminants, and to identify areas requiring further research. The following equation for CH(4) prediction was formulated using only dry matter intake (DMI) and has been adopted in Japan to estimate emissions from ruminant livestock for the National GHG Inventory Report: Y = -17.766 + 42.793X - 0.849X(2), where Y is CH(4) production (L/day) and X is DMI (kg/day). Technologies for the mitigation of CH(4) emissions from ruminants include increasing productivity by improving nutritional management, the manipulation of ruminal fermentation by changing feed composition, the addition of CH(4) inhibitors, and defaunation. Considering the importance of ruminant livestock, it is essential to establish economically feasible ways of reducing ruminant CH(4) production while improving productivity; it is therefore critical to conduct a full system analysis to select the best combination of approaches or new technologies to be applied under long-term field conditions.